MELANOMA CANCER - 20210031

A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma

For more information please visit: https://clinicaltrials.gov/study/NCT06054555?term=20210031&rank=1